Literature DB >> 6413448

Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.

M Jacobson, Y R Sharma, E Cotlier, J D Hollander.   

Abstract

Sorbitol, resulting from glucose metabolism through aldose reductase, may play a role in diabetic complications such as cataracts, neuropathy, and vasculopathy. Sulindac (Clinoril) and sorbinil, two inhibitors of aldose reductase, decreased sorbitol formation in cataract or nerve tissue incubated in high glucose TC-199 media. Sulindac, a widely used anti-rheumatic drug, may have clinical applications in preventing diabetic complications.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6413448

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  -to: Gardiner TA, Anderson HR, Degenhardt T et al. (2003) prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug. Diabetologia 46:1269-1275.

Authors:  S K Biswas; J B Lopes de Faria; J M Lopes de Faria
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

Review 2.  Clinical pharmacokinetics of sulindac. A dynamic old drug.

Authors:  N M Davies; M S Watson
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

3.  Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug.

Authors:  T A Gardiner; H R Anderson; T Degenhardt; S R Thorpe; J W Baynes; D B Archer; A W Stitt
Journal:  Diabetologia       Date:  2003-07-12       Impact factor: 10.122

4.  Diabetic cataract-pathogenesis, epidemiology and treatment.

Authors:  Andreas Pollreisz; Ursula Schmidt-Erfurth
Journal:  J Ophthalmol       Date:  2010-06-17       Impact factor: 1.909

5.  Effects of aldose reductase inhibition on the retina and health indices of streptozotocin-diabetic rats.

Authors:  W M Kozak; N A Marker; K K Elmer
Journal:  Doc Ophthalmol       Date:  1986       Impact factor: 2.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.